°æÈñ´ëÇб³º´¿ø(º´¿øÀå ÀÓ¿µÁø) ³»°ú º¯ÀڹΠÀü°øÀÇ°¡ Á¦1ÀúÀÚ·Î Âü¿©ÇÑ ‘¿°Áõ¼º ÀåÁúȯ ȯÀÚÀÇ °áÇٹ߻ý À§Çè’¿¡ ´ëÇÑ ³í¹® 2ÆíÀÌ SCI Àú³Î¿¡ µîÀçµÇ¾ú´Ù.
ù ¹ø° ³í¹®Àº ‘Scandinavian Journal of Gastroenterolgy’ 2015³â 1¿ùÈ£¿¡ °ÔÀçµÆÀ¸¸ç ³í¹®¸íÀº ‘Risks for opportunistic tuberculosis infection in a cohort of 873 patients with inflammatory bowel disease receiving a tumor necrosis factor-α inhibitor’ (Ç×TNF Á¦Á¦ »ç¿ëÈÄ »ý±ä ±âȸ °áÇÙ °¨¿°: ´Ù±â°ü ¿¬±¸)ÀÌ´Ù.
Journal of Korean Medical Science 2015³â 2È£¿¡ °ÔÀçµÈ µÎ ¹ø° ³í¹®Àº ‘The Risk of Tuberculosis in Korean Patients with Inflammatory Bowel Disease Receiving Tumor Necrosis Factor-α Blockers’(Ç×TNFÁ¦Á¦ Ä¡·á¸¦ ¹ÞÀº Çѱ¹ ¿°Áõ¼º ÀåÁúȯ ȯÀÚ¿¡¼ ¹ß»ýÇÏ´Â °áÇÙÀ§Çè ºÐ¼®)ÀÌ´Ù.
º¯ÀڹΠÀü°øÀÇ´Â “ÃÖ±Ù ¾Æ½Ã¾Æ¿¡¼ ¿°Áõ¼º ÀåÁúȯÀÌ ºü¸¥ ¼Óµµ·Î ´Ã¾î³ª°í ÀÖ´Â ¹Ý¸é, À¯·´°ú ¹Ì±¹¿¡ ºñÇØ Ç×TNF Á¦Á¦ »ç¿ë¿¡ ´ëÇÑ ¿¬±¸°¡ ¸¹ÀÌ ÁøÇàµÇÁö ¾ÊÀº »óȲ”À̶ó¸ç “ƯÈ÷ ¿ì¸®³ª¶ó¿Í °°ÀÌ °áÇÙ ¹ß»ý·üÀÌ ³ôÀº ³ª¶ó¿¡¼ Ç×TNFÁ¦Á¦ ³²¿ëÀº Å« ¹®Á¦¸¦ ÃÊ·¡ÇÒ ¼ö Àֱ⠶§¹®¿¡ Ç×TNFÁ¦Á¦·Î Ä¡·á¹ÞÀº ±¹³» ¿°Áõ¼º ÀåÁúȯ ȯÀÚµéÀÇ °áÇÙ ¹ß»ý À§Ç輺À» ºÐ¼®Çß´Ù.”°í ¹àÇû´Ù.
¿¬±¸ °á°ú, Ç×TNF Á¦Á¦¸¦ »ç¿ëÇÑ ¿°Áõ¼º ÀåÁúȯ ȯÀڵ鿡°Ô¼ °áÇÙÀÇ À§Ç輺ÀÌ »ó´çÈ÷ ³ô¾ÆÁ³À¸¸ç, ´õºÒ¾î Æó°áÇÙ ¹ß»ý À§ÇèÀÌ ´õ ³ôÀ½À» È®ÀÎÇß´Ù. ¿¬±¸ÁøÀº ÀÌ·¯ÇÑ °á°ú¸¦ Åä´ë·Î Ç×TNF Á¦Á¦¸¦ »ç¿ëÇϴ ȯÀÚµéÀº ÈäºÎ x-ray °Ë»ç¸¦ ÅëÇØ Áö¼ÓÀûÀÎ ¸ð´ÏÅ͸µÀÌ ÇÊ¿äÇÏ´Ù°í Á¦¾ÈÇß´Ù.
|